Sara R. Fagerlie, PhD, CHCP
@cancercommunicator.com
Founder of CancerCommunicator.com - Dedicated to improving the care of patients with cancer through news and clinician education.
Pinned
📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
"We’re dismantling some of our tattered safety net and risking the lives of fellow Americans." Worth the read. Gift article #medsky #Medicaid impacts of #bigbeautifulbill
www.nytimes.com/2026/01/03/o...
www.nytimes.com/2026/01/03/o...
Opinion | Trump’s Cuts Are About to Make Health Care Even Worse
www.nytimes.com
January 4, 2026 at 12:15 PM
"We’re dismantling some of our tattered safety net and risking the lives of fellow Americans." Worth the read. Gift article #medsky #Medicaid impacts of #bigbeautifulbill
www.nytimes.com/2026/01/03/o...
www.nytimes.com/2026/01/03/o...
JAMA Most views articles of 2025. #MEDSKY bit.ly/3KZh7CK
December 23, 2025 at 2:31 PM
JAMA Most views articles of 2025. #MEDSKY bit.ly/3KZh7CK
Reposted by Sara R. Fagerlie, PhD, CHCP
Reposted by Sara R. Fagerlie, PhD, CHCP
📣lidERA trial📣
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25
December 11, 2025 at 5:15 AM
📣lidERA trial📣
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25
Reposted by Sara R. Fagerlie, PhD, CHCP
Good morning ☀️ Your Day 2 research recap from the San Antonio Breast Cancer Symposium is here! Check out the highlights now: https://bit.ly/SABCS25
#SABCS25 #breastcancerresearch #BreastCancerNews #BreastCancer #breastcancerawareness
#SABCS25 #breastcancerresearch #BreastCancerNews #BreastCancer #breastcancerawareness
December 11, 2025 at 3:22 PM
Good morning ☀️ Your Day 2 research recap from the San Antonio Breast Cancer Symposium is here! Check out the highlights now: https://bit.ly/SABCS25
#SABCS25 #breastcancerresearch #BreastCancerNews #BreastCancer #breastcancerawareness
#SABCS25 #breastcancerresearch #BreastCancerNews #BreastCancer #breastcancerawareness
Reposted by Sara R. Fagerlie, PhD, CHCP
LBCA was proud to sponsor the special session on lobular breast cancer at SABCS! #ILC #ILCawareness #lobularbreastcancer #SABCS25
December 11, 2025 at 3:34 PM
LBCA was proud to sponsor the special session on lobular breast cancer at SABCS! #ILC #ILCawareness #lobularbreastcancer #SABCS25
Reposted by Sara R. Fagerlie, PhD, CHCP
A new, highly sensitive liquid biopsy test may better detect minimal residual disease (MRD) — tiny traces of cancer left after treatment. This could one day help identify who is at higher risk of recurrence and who may safely skip extra therapy. Learn more: https://bit.ly/SABCS25
#SABCS25 #bcsm
#SABCS25 #bcsm
December 11, 2025 at 3:44 PM
A new, highly sensitive liquid biopsy test may better detect minimal residual disease (MRD) — tiny traces of cancer left after treatment. This could one day help identify who is at higher risk of recurrence and who may safely skip extra therapy. Learn more: https://bit.ly/SABCS25
#SABCS25 #bcsm
#SABCS25 #bcsm
Reposted by Sara R. Fagerlie, PhD, CHCP
New data presented at #SABCS25 shows that adding a breast MRI to a diagnostic mammogram does not improve five-year recurrence rates for patients with stage I/II HR negative breast cancer. spr.ly/63320C8iqk #OncSky #EndCancer
December 11, 2025 at 3:46 PM
New data presented at #SABCS25 shows that adding a breast MRI to a diagnostic mammogram does not improve five-year recurrence rates for patients with stage I/II HR negative breast cancer. spr.ly/63320C8iqk #OncSky #EndCancer
Reposted by Sara R. Fagerlie, PhD, CHCP
At #SABCS25, new HER2CLIMB-05 results showed Tukysa + Herceptin + Perjeta helped people live longer without their metastatic #breastcancer progressing — 25 months vs. 16.
💊 Because Tukysa is taken orally, this combo may also be easier for many people to manage.
Learn more: https://bit.ly/SABCS25
💊 Because Tukysa is taken orally, this combo may also be easier for many people to manage.
Learn more: https://bit.ly/SABCS25
December 11, 2025 at 4:19 PM
At #SABCS25, new HER2CLIMB-05 results showed Tukysa + Herceptin + Perjeta helped people live longer without their metastatic #breastcancer progressing — 25 months vs. 16.
💊 Because Tukysa is taken orally, this combo may also be easier for many people to manage.
Learn more: https://bit.ly/SABCS25
💊 Because Tukysa is taken orally, this combo may also be easier for many people to manage.
Learn more: https://bit.ly/SABCS25
Want to see the lasted posts from #ASH25 or #SABCS25 check out the conference feed! #cansky #oncsky #medsky
📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
December 6, 2025 at 6:15 PM
Reposted by Sara R. Fagerlie, PhD, CHCP
December 6, 2025 at 6:01 PM
Reposted by Sara R. Fagerlie, PhD, CHCP
#ASH25 (Abs 47): Encouraging early results (N=21, median age 70 y) from ph2 SAVE trial of all-oral regimen: revumenib + decitabine/cedazuridine + venetoclax in ND NPM1- or KMT2A-mutated AML. 86% ORR, 81% CR/CRh. #Medsky #cansky #oncsky #AML
www.cancercommunicator.com/oral-menin-b...
www.cancercommunicator.com/oral-menin-b...
December 6, 2025 at 6:03 PM
Reposted by Sara R. Fagerlie, PhD, CHCP
Symptom-based PFS CLL/SLL #ASH25
- 606 pts in ALPINE (zanu v ibru)
- longitudinal fatigue, insomnia, N/V associated with increased risk of PD (regardless of BTKi)
- zanu: lower odds of symptom worsening vs ibrutinib
More trial data demonstrating prognostic value of PROs! #leusm #lymsm
- 606 pts in ALPINE (zanu v ibru)
- longitudinal fatigue, insomnia, N/V associated with increased risk of PD (regardless of BTKi)
- zanu: lower odds of symptom worsening vs ibrutinib
More trial data demonstrating prognostic value of PROs! #leusm #lymsm
December 2, 2025 at 11:19 PM
Backdoor privatization of Medicare “When third-party entities are paid based on the volume of denied services, there is a clear risk that care that is medically necessary for certain patients will be inappropriately denied in pursuit of savings" www.kuow.org/stories/thou... #medsky #medicare
Thousands of Washington state Medicare users could soon have claims denied by AI
Starting Jan. 1, traditional Medicare recipients in Washington state will face a new hurdle to get certain procedures covered — private AI companies that get paid based on how many claims they deny.
www.kuow.org
December 2, 2025 at 2:29 PM
Backdoor privatization of Medicare “When third-party entities are paid based on the volume of denied services, there is a clear risk that care that is medically necessary for certain patients will be inappropriately denied in pursuit of savings" www.kuow.org/stories/thou... #medsky #medicare
"Nvidia and AMD and...Hewlett Packard Enterprise and Dell have already agreed to build facilities within the national labs...Some data will be shared with AI companies but...the government would withhold sensitive information that could put national security at risk" nyti.ms/3XR2uUG
Trump Orders Construction of A.I. Platform to Use Troves of Government Data for Research
www.nytimes.com
November 25, 2025 at 7:18 PM
"Nvidia and AMD and...Hewlett Packard Enterprise and Dell have already agreed to build facilities within the national labs...Some data will be shared with AI companies but...the government would withhold sensitive information that could put national security at risk" nyti.ms/3XR2uUG
Reposted by Sara R. Fagerlie, PhD, CHCP
Welcome to the Science feed!
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
February 10, 2024 at 3:08 PM
Welcome to the Science feed!
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
Reposted by Sara R. Fagerlie, PhD, CHCP
#ESMO25: Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free and overall survival in cisplatin-ineligible patients with muscle-invasive #BladderCancer in the phase III KEYNOTE-905/EV-303 trial
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
October 18, 2025 at 3:30 PM
#ESMO25: Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free and overall survival in cisplatin-ineligible patients with muscle-invasive #BladderCancer in the phase III KEYNOTE-905/EV-303 trial
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
October 17, 2025 at 7:08 PM
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
The addition of local consolidative therapy to osimertinib improved PFS vs osimertinib alone in patients with EGFR-mutated locally advanced or metastatic #NSCLC (LBA72) NorthStar teial #ESMO25 bit.ly/4qnGuht #lcsm
Local consolidative therapy combined with osimertinib improves progression-free survival in metastatic EGFR-mutant NSCLC
Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting
dailyreporter.esmo.org
October 17, 2025 at 5:04 PM
The addition of local consolidative therapy to osimertinib improved PFS vs osimertinib alone in patients with EGFR-mutated locally advanced or metastatic #NSCLC (LBA72) NorthStar teial #ESMO25 bit.ly/4qnGuht #lcsm
Reposted by Sara R. Fagerlie, PhD, CHCP
At #ESMO25, explore how AI & digital tools are shaping oncology:
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
October 17, 2025 at 5:30 AM
At #ESMO25, explore how AI & digital tools are shaping oncology:
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇
October 17, 2025 at 9:35 AM
It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇